HOME >> BIOLOGY >> NEWS
New threat to commercial fishing

Commercial fishing practices can reduce genetic diversity in fish populations, possibly threatening their productivity and adaptability to environmental change, new research has found.

An Australian zoologist now at the University of Melbourne, along with colleagues from the United Kingdom and New Zealand, was the first to record a decline in the genetic diversity of a commercially exploited marine species. Their findings, published in the latest volume of the Proceedings of the National Academy of Sciences, shout a warning that could force a rethink to current fisheries management and the research focus into sustainable fishing.

Dr Greg Adcock analysed the DNA found in scales preserved from two populations of New Zealand snapper collected from the 1950s to 1998. One population had been commercially fished since the late 1800s. The other was a 'virgin' population, being subjected to subsistence and recreational fishing only until the scale collection began.

Adcock and colleagues found that the 'virgin' population from Tasman Bay on New Zealand's South Island had suffered an unexpected decline in genetic diversity, starting from the time it began to be commercially exploited in the 1950s.

The other population, from the North Island's Hauraki Bay, showed no decline in genetic diversity in the nearly 50 years to 1998.

The paper reports that the Tasman Bay's effective population size (the number of fish in the population capable of breeding) is100,000 times fewer than its total number, and several orders of magnitude lower than expected.

"In Tasman Bay, commercial fishing has often reduced total numbers to as low as about one million. This leaves only a few hundred fish to contribute to the next generation, a dangerously low genetic base from which to sustain a population," says Adcock.

"With a high effective population you can retain a large amount of rare genetic variation. Such variation is lost as numbers
'"/>

Contact: Jason Major
jmajor@unimelb.edu.au
61-3-8344-0181
University of Melbourne
13-Aug-2002


Page: 1 2 3

Related biology news :

1. Scientists decipher genetic code of biothreat pathogen
2. Identifying tick genes could halt disease, bioterrorism threat
3. UC Irvine scientists to develop vaccine to combat bioterrorism threat from deadly bacteria
4. Increasing international insect threat to stored food
5. Report outlines steps needed to lessen smallpox threat
6. Computer model shows increased US threat from soybean rust
7. Danger spots identified for threatened grizzly bear
8. 51 globally threatened species get new lease on life in the Caucasus
9. Disease threatens cucumbers, pumpkins, and other vine crops
10. Urban runoff poses increased health threat for surfers, other beach users, UCI study shows
11. City rain run-off poses threat to coastal water users

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New threat commercial fishing

(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
(Date:8/28/2015)... -- According to a new market research ... Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem Cells, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 2,150.48 Million in 2015, ... 2020. Browse 74 Tables and 95 ...
(Date:8/28/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, ... June 30, 2015, corporate highlights, and near-term milestones.  ... available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment for ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... venture capital funds, investment firms and animal health companies to hear from animal ... $160 million. Several have also received licensing agreements or distribution contracts. This ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
Cached News: